-
Your selected country is
Brazil
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Anti-HLA-DR Purified
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Store vials at 2° to 8°C. Conjugated forms should not be frozen and should be protected from exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.
The Anti-HLA-DR antibody, clone L243, is derived from the hybridization of NS-1/1-Ag4 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with the human lymphoblastoid B-cell line RPMI 8866.
The Anti-HLA-DR antibody recognizes a human class II major histocompatibility complex (MHC) antigen. The antigen is a transmembrane glycoprotein composed of α- and β-subunits that have molecular weights of 36 and 27 kilodaltons (kDa), respectively.
Development References (11)
-
Brodsky FM. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.. Immunogenetics. 1984; 19(3):179-94. (Biology). View Reference
-
Edwards JA, Durant BM, Jones DB, Evans PR, Smith JL. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression.. J Immunol. 1986; 137(2):490-7. (Biology). View Reference
-
Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody.. Proc Natl Acad Sci USA. 1981; 78(3):1791-5. (Biology). View Reference
-
Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line.. J Immunol. 1980; 125(1):293-9. (Biology). View Reference
-
Levacher M, Tallet S, Dazza MC, Dournon E, Rouveix B, Pocidalo JJ. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.. Clin Exp Immunol. 1990; 81(2):177-82. (Biology). View Reference
-
Stites DP, Casavant CH, McHugh TM, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence.. Clin Immunol Immunopathol. 1986; 38(2):161-77. (Biology). View Reference
-
Terstappen LW, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990; 48(2):138-148. (Biology). View Reference
-
Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection.. J Immunol. 1987; 139(11):3802-7. (Biology). View Reference
-
Warnke R, Miller R, Grogan T, Pederson M, Dilley J, Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma.. N Engl J Med. 1980; 303(6):293-300. (Biology). View Reference
-
Warnke RA, Levy R. Detection of T and B cell antigens with hybridoma monoclonal antibodies: a biotinavidin-horseradish peroxidase method. J Histochem Cytochem. 1980; 28:771-776. (Biology).
-
Zipf RF, Fox R, Dilley J, Levy R. Definition of the high risk ALL patient by immunologic phenotyping withmonoclonal antibodies. Cancer Res. 1981; 41:4786. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.